Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study

BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively. High costs with adverse events (AE) of sorafenib might limit sorafenib dosage, further affecting therapeutic respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, Wang-De, Peng, Cheng-Yuan, Chuang, Po-Heng, Lai, Hsueh-Chou, Cheng, Ken-Sheng, Chou, Jen-Wei, Chen, Yang-Yuan, Yu, Cheng-Ju, Feng, Chun-Lung, Su, Wen-Pang, Chen, Sheng-Hung, Kao, Jung-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847248/
https://www.ncbi.nlm.nih.gov/pubmed/27117280
http://dx.doi.org/10.1186/s12876-016-0464-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847248/
https://www.ncbi.nlm.nih.gov/pubmed/27117280
http://dx.doi.org/10.1186/s12876-016-0464-x

Ejemplares similares